Physician profile
Uma Jamched
NPI 1265434252
$4,905.68
in general payments reported to CMS, 2019-2025
40 companies · $1,213 in 2025
The $1,213 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.43 · 2020: $208 · 2021: $373 · 2022: $609 · 2023: $1,345 · 2024: $1,117 · 2025: $1,213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,516 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,515.67 |
| Education | $159.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $800.47 | 2021-2025 | |
| Astellas Pharma US INC | $540.10 | 2021-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $356.52 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $352.44 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $325.86 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Paratek Pharmaceuticals, INC. | $285.38 | 2022-2025 | Nuzyra |
| Astrazeneca Pharmaceuticals Lp | $269.49 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $191.52 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $155.48 | 2022-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $151.56 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.27 | 2019-2024 | Xifaxan |
| Lundbeck LLC | $139.61 | 2024-2025 | Rexulti |
| Eisai INC. | $120.34 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $94.05 | 2021-2025 | |
| Amgen INC. | $80.48 | 2022-2025 | Otezla, Repatha, Repatha |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $73.24 | 2024 | Caplyta |
| Abbott Laboratories | $64.88 | 2023-2025 | Freestyle Libre 3 |
| Boston Scientific Corporation | $64.44 | 2024-2025 | Watchman Access System |
| Qol Medical, LLC | $63.88 | 2022-2023 | Sucraid |
| Dexcom, INC. | $61.07 | 2024-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $57.12 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.56 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $46.73 | 2022-2024 | |
| Exact Sciences Corporation | $41.33 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $39.13 | 2019-2025 | Gardasil 9, Capvaxive |
| Medtronic, INC. | $35.94 | 2024 | Interstim |
| Kowa Pharmaceuticals America, INC. | $30.18 | 2023-2024 | Livalo |
| Phadia US INC. | $29.59 | 2022-2023 | Immunocap |
| Amarin Pharma, INC. | $29.35 | 2020-2021 | |
| Saluda Medical Americas, INC. | $27.20 | 2024 | Evoke |
| Optos, INC. | $25.61 | 2020 | |
| Philips North America LLC | $23.64 | 2024 | (Ck7) Extended Holter |
| Nevro Corp. | $23.40 | 2022 | |
| Echosens North America, INC. | $21.93 | 2025 | Fibroscan |
| Neurocrine Biosciences, INC. | $19.48 | 2023 | Ingrezza |
| Bausch Health US, LLC | $19.40 | 2022 | |
| Redhill Biopharma INC. | $17.18 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.64 | 2022 | |
| Corium, LLC | $15.09 | 2023 | Adlarity |
| Metacel Pharmaceuticals LLC | $6.10 | 2023 | Ozobax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uma Jamched listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.